Английская Википедия:Bicifadine
Шаблон:Short description Шаблон:Drugbox
Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.[1][2][3]
In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain.[4][5][6] XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008;[7] XTL terminated the agreement in 2010.[8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.[9]
Bicifadine has a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.[10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."[11]
See also
References
Шаблон:Analgesics Шаблон:Antidepressants Шаблон:Monoamine reuptake inhibitors
- ↑ Шаблон:Cite journal
- ↑ SEC Filing: Wyeth-DOV Restated License Agreement Page accessed July 15, 2015]
- ↑ Шаблон:Cite book
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Fierce Biotech. December 9, 2008 Tiny XTL cuts costs, jobs
- ↑ Шаблон:Cite web
- ↑ Fierce Biotech July 22, 2010 Euthymics lands $24M to fund antidepressant work
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal